Sensus Healthcare, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SRTS$3.30+3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Six Months Ended June 30, | ||
|---|---|---|
| (in thousands) | 2026 | 2025 |
| Cash flows from operating activities | ||
| Net loss | $(11,375) | $(3,609) |
| Adjustments to reconcile net loss to net cash, restricted cash, and cash equivalents (used in) provided by operating activities: | ||
| Depreciation | 182 | 185 |
| Amortization of right-of-use asset | 123 | 118 |
| Provision for product warranties | 134 | 138 |
| Stock-based compensation | 140 | 146 |
| Deferred income taxes | 4,079 | (613) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 4,361 | 7,109 |
| Inventories | (4,839) | (3,176) |
| Prepaid inventory | 915 | 666 |
| Other current assets | (62) | (842) |
| Other noncurrent assets | 135 | 117 |
| Accounts payable and accrued expenses | (176) | 554 |
| Operating lease liability | (128) | (118) |
| Deferred revenue | (233) | (35) |
| Product warranties | (142) | (200) |
| Net cash (used in) provided by operating activities | (6,886) | 440 |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (11) | (34) |
| Net cash used in investing activities | (11) | (34) |
| Cash flows from financing activities | ||
| Repurchase of common stock | — | (300) |
| Net cash used in financing activities | — | (300) |
| Net (decrease) increase in cash, restricted cash, and cash equivalents | (6,897) | 106 |
| Cash, restricted cash, and cash equivalents – beginning of period | 22,083 | 22,056 |
| Cash, restricted cash, and cash equivalents – end of period | $15,186 | $22,162 |
| Supplemental disclosure of cash flow information: | ||
| Interest paid | $— | $— |
| Income tax paid | $8 | $979 |
| Supplemental schedule of noncash investing and financing transactions: | ||
| Transfer of inventory to property and equipment | $943 | $868 |
| Lease liability arising from obtaining right-of-use-assets | $— | $111 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.